118 related articles for article (PubMed ID: 9259969)
1. Absence of p16 gene (CDKN2) deletions in microdissected primary breast carcinoma specimens.
Calvano JE; Rush EB; Tan LK; Rosen PP; Borgen PI; Van Zee KJ
Ann Surg Oncol; 1997; 4(5):416-20. PubMed ID: 9259969
[TBL] [Abstract][Full Text] [Related]
2. Alterations of p16-pRb pathway and chromosome locus 9p21-22 in sporadic invasive breast carcinomas.
Gorgoulis VG; Koutroumbi EN; Kotsinas A; Zacharatos P; Markopoulos C; Giannikos L; Kyriakou V; Voulgaris Z; Gogas I; Kittas C
Mol Med; 1998 Dec; 4(12):807-22. PubMed ID: 9990866
[TBL] [Abstract][Full Text] [Related]
3. Chromosome 9p allelic loss and p16/CDKN2 in breast cancer and evidence of p16 inactivation in immortal breast epithelial cells.
Brenner AJ; Aldaz CM
Cancer Res; 1995 Jul; 55(13):2892-5. PubMed ID: 7796417
[TBL] [Abstract][Full Text] [Related]
4. Deletion and mutation analyses of the P16/MTS-1 tumor suppressor gene in human ductal pancreatic cancer reveals a higher frequency of abnormalities in tumor-derived cell lines than in primary ductal adenocarcinomas.
Huang L; Goodrow TL; Zhang SY; Klein-Szanto AJ; Chang H; Ruggeri BA
Cancer Res; 1996 Mar; 56(5):1137-41. PubMed ID: 8640773
[TBL] [Abstract][Full Text] [Related]
5. Mutational analysis of CDKN2 (MTS1/p16ink4) in human breast carcinomas.
Xu L; Sgroi D; Sterner CJ; Beauchamp RL; Pinney DM; Keel S; Ueki K; Rutter JL; Buckler AJ; Louis DN
Cancer Res; 1994 Oct; 54(20):5262-4. PubMed ID: 7923151
[TBL] [Abstract][Full Text] [Related]
6. Alterations of CDKN2 (p16) in non-small cell lung cancer.
de Vos S; Miller CW; Takeuchi S; Gombart AF; Cho SK; Koeffler HP
Genes Chromosomes Cancer; 1995 Nov; 14(3):164-70. PubMed ID: 8589032
[TBL] [Abstract][Full Text] [Related]
7. Mechanism of inactivation of CDKN2 and MTS2 in non-small cell lung cancer and association with advanced stage.
Nakagawa K; Conrad NK; Williams JP; Johnson BE; Kelley MJ
Oncogene; 1995 Nov; 11(9):1843-51. PubMed ID: 7478613
[TBL] [Abstract][Full Text] [Related]
8. The multiple tumor suppressor 1/cyclin-dependent kinase inhibitor 2 gene in human central nervous system primitive neuroectodermal tumor.
Raffel C; Ueki K; Harsh GR; Louis DN
Neurosurgery; 1995 May; 36(5):971-4; discussion 974-5. PubMed ID: 7791990
[TBL] [Abstract][Full Text] [Related]
9. Deletion analysis of the p16/CDKN2 gene in head and neck squamous cell carcinoma using quantitative polymerase chain reaction method.
Rawnsley JD; Srivatsan ES; Chakrabarti R; Billings KR; Wang MB
Arch Otolaryngol Head Neck Surg; 1997 Aug; 123(8):863-7. PubMed ID: 9260553
[TBL] [Abstract][Full Text] [Related]
10. Differential inactivation of CDKN2 and Rb protein in non-small-cell and small-cell lung cancer cell lines.
Kelley MJ; Nakagawa K; Steinberg SM; Mulshine JL; Kamb A; Johnson BE
J Natl Cancer Inst; 1995 May; 87(10):756-61. PubMed ID: 7563154
[TBL] [Abstract][Full Text] [Related]
11. Alterations of retinoblastoma, p53, p16(CDKN2), and p15 genes in human astrocytomas.
Tsuzuki T; Tsunoda S; Sakaki T; Konishi N; Hiasa Y; Nakamura M
Cancer; 1996 Jul; 78(2):287-93. PubMed ID: 8674005
[TBL] [Abstract][Full Text] [Related]
12. MTS1/p16/CDKN2 lesions in primary glioblastoma multiforme.
Moulton T; Samara G; Chung WY; Yuan L; Desai R; Sisti M; Bruce J; Tycko B
Am J Pathol; 1995 Mar; 146(3):613-9. PubMed ID: 7887443
[TBL] [Abstract][Full Text] [Related]
13. Molecular analysis of P16(Ink4)/CDKN2 and P15(INK4B)/MTS2 genes in primary human testicular germ cell tumors.
Heidenreich A; Gaddipati JP; Moul JW; Srivastava S
J Urol; 1998 May; 159(5):1725-30. PubMed ID: 9554401
[TBL] [Abstract][Full Text] [Related]
14. Molecular analysis of the INK4A and INK4B gene loci in human breast cancer cell lines and primary carcinomas.
Bisogna M; Calvano JE; Ho GH; Orlow I; Cordón-Cardó C; Borgen PI; Van Zee KJ
Cancer Genet Cytogenet; 2001 Mar; 125(2):131-8. PubMed ID: 11369056
[TBL] [Abstract][Full Text] [Related]
15. Low frequency of CDKN2 mutation in endometrial carcinomas.
Peiffer SL; Bartsch D; Whelan AJ; Mutch DG; Herzog TJ; Goodfellow PJ
Mol Carcinog; 1995 Aug; 13(4):210-2. PubMed ID: 7646759
[TBL] [Abstract][Full Text] [Related]
16. Sporadic CDKN2 (MTS1/p16ink4) gene alterations in human ovarian tumours.
Schuyer M; van Staveren IL; Klijn JG; vd Burg ME; Stoter G; Henzen-Logmans SC; Foekens JA; Berns EM
Br J Cancer; 1996 Oct; 74(7):1069-73. PubMed ID: 8855976
[TBL] [Abstract][Full Text] [Related]
17. p16/CDKN2 and CDK4 gene mutations in sporadic melanoma development and progression.
Piccinin S; Doglioni C; Maestro R; Vukosavljevic T; Gasparotto D; D'Orazi C; Boiocchi M
Int J Cancer; 1997 Feb; 74(1):26-30. PubMed ID: 9036865
[TBL] [Abstract][Full Text] [Related]
18. Methylation of the 5' CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing.
Gonzalez-Zulueta M; Bender CM; Yang AS; Nguyen T; Beart RW; Van Tornout JM; Jones PA
Cancer Res; 1995 Oct; 55(20):4531-5. PubMed ID: 7553622
[TBL] [Abstract][Full Text] [Related]
19. Alterations of p16/CDKN2, p53 and ras genes in oral squamous cell carcinomas and premalignant lesions.
Matsuda H; Konishi N; Hiasa Y; Hayashi I; Tsuzuki T; Tao M; Kitahori Y; Yoshioka N; Kirita T; Sugimura M
J Oral Pathol Med; 1996 May; 25(5):232-8. PubMed ID: 8835820
[TBL] [Abstract][Full Text] [Related]
20. Mutational analysis of the CDKN2 (MTS1/p16ink4A) gene in primary B-cell lymphomas.
Uchida T; Watanabe T; Kinoshita T; Murate T; Saito H; Hotta T
Blood; 1995 Oct; 86(7):2724-31. PubMed ID: 7670111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
